Voruciclib 是一种具有口服活性的选择性 CDK 抑制剂，Ki 值为 0.626 nM-9.1 nM。 Voruciclib 有效阻断 CDK9，MCL-1 的转录调节因子。 Voruciclib 在多种弥漫性大 B 细胞淋巴瘤 (DLBCL) 模型中抑制 MCL-1 的表达。
| Cas No. | 1000023-04-0 |
| Canonical SMILES | O=C1C=C(C2=C(Cl)C=C(C(F)(F)F)C=C2)OC3=C1C(O)=CC(O)=C3[C@@]4([H])[C@H](CO)N(C)CC4 |
| 分子式 | C22H19ClF3NO5 |
| 分子量 | 469.8 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Voruciclib is a pan-inhibitor of cyclin-dependent kinases (CDKs; Kis = 0.626-9.1 nM).1 It is selective for CDKs over male germ cell associated kinase (MAK) and intestinal cell kinase (ICK; Kis = 259 and 481 nM, respectively), in a panel of 48 kinases. Voruciclib decreases myeloid cell leukemia-1 (Mcl-1) levels and increases cleaved poly(ADP-ribose) polymerase (PARP) levels in six diffuse large B-cell lymphoma (DLBCL) cell lines when used at concentrations ranging from 0.5 to 5 μM. It reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model when administered at a dose of 200 mg/kg. |1. Dey, J., Deckwerth, T.L., Kerwin, W.S., et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition. Sci. Rep. 7(1), 18007 (2017). |
